Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

3Q09 Corporate Highlights:

  • Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd.
  • Made significant progress in commercial readiness activities
  • Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Appointed Bradford S. Goodwin to board as director and Audit Committee chairman

Upcoming 2009 Milestones:

  • FDA PDUFA date November 16, 2009 for Qutenza NDA to manage pain associated with PHN

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.

During the third quarter of 2009, NeurogesX prioritized three key initiatives: 1) supporting the ongoing U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Qutenza for postherpetic neuralgia (PHN), 2) preparing for potential commercial launch of Qutenza in the United States pending FDA approval and 3) supporting Astellas Pharma Europe Ltd., the commercial partner for Qutenza in Europe, the Middle East and Africa, in their efforts to prepare for a Qutenza launch in the European Union in 2010.

In the U.S., NeurogesX is currently awaiting a decision from FDA regarding its NDA for Qutenza to manage pain associated with PHN. The agency has assigned an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009. In preparation for the possible approval and subsequent planned launch of Qutenza in the United States in the first half of 2010, the Company continued to make significant advances in a number of key product laun
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... after dealing with certain matters, including the appointment of ... on March 26, 2015 (the "Meeting") was adjourned, as ... 2015 at 11:00 a.m. ( Toronto ... changed from that previous disclosed. The Meeting will reconvene ...
(Date:3/26/2015)... 2015  BioNano Genomics, Inc., the leader in genome ... as chief commercial officer. Salyer has more than 20 ... in life sciences. At BioNano, Salyer will oversee the ... platform to assemble a comprehensive view of complex genomes ... 32 institutions located in the United States ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Technology (NIST) has issued a new ruler, and even for ... records. Designed to be the most accurate commercially available "meter ... standard for X-ray diffractionboasts uncertainties below a femtometer. That,s 0.000 ... a neutron. The new ruler is in the form ...
... , , , ... a prospective registry showed good safety in a broad population of patients ... Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI). , , ... of major adverse cardiac events (MACE) was 6.7 percent and the rate ...
... SAN DIEGO, Sept. 22 SoluLinK, Inc., a leader ... Catalyst, making conjugation at least 20 times faster than before ... , , Up to now, researchers, conjugation ... poor yields, poor quality and more labor and time consuming ...
Cached Biology Technology:New NIST nano-ruler sets some very small marks 2OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI 3SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100% Yields 2
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
(Date:3/5/2015)... March 5, 2015 In Brazil ... companies already using these solutions and 42 percent planning to ... latter, approximately 25 percent of the companies will be investing ... the majority of companies in the region are currently opting ... hybrid model will command significant attention in the coming years. ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... in their genes" is a common refrain from scientists when ... and beyond. Up until now, research has focused on ... levels of HDL ("good") cholesterol. But researchers at Albert ... of Psychology of Yeshiva University have found that personality ...
... Preventice, Inc. , a developer of mobile health ... it is the latest to join medical device ... payors that are integrating with Qualcomm Life Inc., ... their 2net™ Ecosystem. (Logo: http://photos.prnewswire.com/prnh/20120417/CG89172LOGO ...
... Diego have discovered that a small dose of a commonly ... affects their ability to recruit their nestmates to otherwise good ... this week,s issue of the Journal of Experimental Biology ... bee-pollinated crops and shed light on one of the main ...
Cached Biology News:'Personality genes' may help account for longevity 2Preventice Expands Options for Wireless Patient Monitoring with Qualcomm Life 2Commonly used pesticide turns honey bees into 'picky eaters' 2
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
... to Uridine Phosphorylase 1 ( Abpromise ... Antigen: Synthetic peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK ... corresponding to amino acids 1-99 of Human ... Gene ID: 7378 ...
Request Info...
Syne-1 (N-19)...
Biology Products: